The High Bar for Gene Therapy CMC
How drug developers can step up to meet regulatory expectations for gene therapy chemistry manufacturing and controls
After well publicized stumbling blocks in the late-90s, vigor was restored to the gene therapy field in 2017 when the U.S. FDA greenlighted two chimeric antigen receptor (CAR) T-cell treatments for acute lymphoblastic leukemia, followed by the first directly administered gene therapy, developed to treat a hereditary form of vision loss.
Years later, there are still only a handful of approvals in the space (two gene therapies and five CAR-T cell therapies),
but pipelines are brimming with potential.
Download the Whitepaper
Complete the form below to download your copy!
You might also be interested in…
mAbs and Their Therapeutic Evolution
White Paper: mAbs and Their Therapeutic EvolutionBy Tracy TreDenick, Head of Regulatory and Quality, and Senior Consultant Monoclonal antibodies (mAbs) elegant specificity has catapulted them to a starring role within the world of precision medicine over the course of...
eBook: Key Considerations in Gene Therapy Manufacturing for Commercialization
eBook: Key Considerations in Gene Therapy Manufacturing for Commercialization “The regulatory landscape for gene therapies is as transforming as the curative nature of a transgene. In 2012, we saw the introduction of the Breakthrough Therapy Designation. Just when you...
White Paper: 4 Things You Need to Know About Combination Drug Compliance
White Paper: 4 Things You Need to Know About Combination Drug ComplianceCombination products are a fascinating area of the pharmaceutical industry and present great future promise. The segment is projected to reach $115 billion in global sales by the end of 2019. It...